Simultaneous determination of morinidazole and its carbonylation metabolite in human plasma: application to a pharmacokinetic study involving renal insufficiency patients and healthy volunteers

J Pharm Biomed Anal. 2013 Mar 25:76:75-80. doi: 10.1016/j.jpba.2012.11.037. Epub 2012 Dec 13.

Abstract

A novel simple bioanalytical method of high performance liquid chromatography (HPLC) for simultaneous quantification of morinidazole and its carbonylation metabolite (M1) in human plasma was developed and validated. The calibration curves for morinidazole and M1 were linear over concentration ranges of 23.99-1.464×10(4)μgL(-1) and 5.407-3300μgL(-1), respectively. Intra- and inter-day precision and accuracy results satisfied the acceptable criteria for bioanalytical method validation. This method could be a useful method for clinical pharmacokinetic studies of morinidazole and its carbonylation metabolite, and it has been applied to a pharmacokinetic study involving 11 renal insufficiency patients and 11 healthy volunteers.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Adult
  • Anti-Bacterial Agents / pharmacokinetics*
  • Calibration
  • Case-Control Studies
  • Chromatography, High Pressure Liquid / methods*
  • Humans
  • Middle Aged
  • Nitroimidazoles / pharmacokinetics*
  • Renal Insufficiency / complications*
  • Reproducibility of Results

Substances

  • Anti-Bacterial Agents
  • Nitroimidazoles
  • morinidazole